Total Funding
78
50
Total FundingSeries B raised
Growth Score 78 in past quarter
-6 pts
Heat Score 50 in past quarter
-6 pts
Company Performance Metrics
Score
Trend
AI Content may contain mistakes and is not legal, financial or investment advice.Learn more.
Growth Score - The measure of growth based on company activity, operational metrics, and investments
Growth Trend - The change in the growth score over the given time period
Heat Score - The measure of the market interest, media activity, and Crunchbase profile activity
Heat Trend - The change in the heat score over the given time period
Recent Milestones
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
Raised Funding Round
Jan 1, 1970
Lorem ipsum dolor sit amet, consectetur
See more interactive data and historical milestones on desktop for the best experience
37612
Citryll is a developer of pharmaceutical drugs used to treat autoimmune and other human diseases.
Helmuth van Es: CEO- Renato Chirivi: CSO
About the Company
Citryll is a private pharmaceutical company that develops pharmaceutical drugs used to treat autoimmune and other human diseases. The company offers formation, function, and clearance of NETs downstream of the protein citrullination pathway catalyzed by Peptidylarginine Deiminase (PAD) enzymes that enable doctors to help in the treatment of lupus,
vasculitis, pulmonary fibrosis, rheumatoid arthritis and organ damage due to sepsis.
Citryll was established in 2015 and is headquartered in Oss, The Netherlands.